Opinion|Videos|October 7, 2024
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Key Takeaways
- Combining BCG and PD-1/PD-L1 inhibitors may enhance antitumor activity through complementary mechanisms, potentially improving outcomes in NMIBC.
- BCG stimulates immune response, while PD-1/PD-L1 inhibitors prevent immune evasion, providing a rationale for their combined use.
Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How might the combination of BCG and PD-1/PD-L1 inhibitors affect antitumor activity compared with using each agent alone?
- What is the rationale for using these therapies in combination?
- How do you think the combination therapies will evolve treatment of non–muscle-invasive bladder cancer (NMIBC)?
- How would the use of PD-1/PD-L1 inhibitors plus BCG in high-risk NMIBC impact patient flow in urology practice?
THE SPEAKER WILL HIGHLIGHT THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
Casdatifan shows activity across treatment settings in advanced ccRCC
4
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
5